AB0391 SIMILAR PHARMACOKINETICS, SAFETY AND TOLERABILITY

OF THE ADALIMUMAB BIOSIMILAR CANDIDATE BI 695501 ADMINISTERED SUBCUTANEOUSLY VIA PREFILLED SYRINGE (PFS) OR AUTOINJECTOR (AI) (VOLTAIRE ® -AI)
. Administration in chronic inflammatory diseases benefits from patient-friendly PFSs or AIs, the development of which requires assessment of PK, safety, immunogenicity, and local tolerability. Objectives: To compare PK, safety, immunogenicity, and tolerability of BI 695501 after subcutaneous (SC) injection using either a PFS or an AI. Methods: In this 16-week randomised, single-dose, open-label, parallel-group study (NCT02606903), 40mg BI 695501 was administered either via PFS or AI in healthy, Caucasian, male, non-athletic volunteers aged 18-65 years with body mass index (BMI) of ≥18 to ≤30 kg/m 2 . The study end points included AUC 0-1032 , C max , and AUC 0-∞ , analysed using an ANOVA model with fixed effects for treatment and BMI group. Safety assessment included the proportion of subjects with drug-related adverse events (AEs). Immunogenicity parameters were: proportion of subjects with binding/neutralising anti-drug antibodies (ADAs), and ADA titers. Results: Seventy-one volunteers were randomised: PFS, n=36; AI, n=35. Key demographic and baseline characteristics were well balanced between the treatment groups. PK end point results are shown in Table 1 . Estimates for AI/PFS geometric mean (gMean) ratios were within the standard bioequivalence acceptance range (80-125%). Mean plasma concentration-time profiles and ‡ AUC values could not be calculated for one subject (Subject 1001-0110), due to the lack of appropriate terminal phase (only one non-BLQ [below the limit of quantification] value in the elimination phase). total exposure for BI 695501 administered via PFS or AI were similar over the observation period; treatment-emergent AEs (TEAEs) and administration site conditions (ASC) are shown in Table 2 . 
